Abstract
In nanoparticle (NP)-mediated drug delivery, liposomes are the most widely used drug carrier, and the only NP system currently approved by the FDA for clinical use, owing to their advantageous physicochemical properties and excellent biocompatibility. Recent advances in liposome technology have been focused on bioconjugation strategies to improve drug loading, targeting, and overall efficacy. In this review, we highlight recent literature reports (covering the last five years) focused on bioconjugation strategies for the enhancement of liposome-mediated drug delivery. These advances encompass the improvement of drug loading/incorporation and the specific targeting of liposomes to the site of interest/drug action. We conclude with a section highlighting the role of bioconjugation strategies in liposome systems currently being evaluated for clinical use and a forward-looking discussion of the field of liposomal drug delivery.
Highlights
Since their first published description in 1964 [1], interest in liposomes as drug carriers and delivery agents has grown exponentially, and they have become the most prominent nanoparticle (NP) drug delivery system approved for use in the clinic
The results showed that cellular uptake of DKD liposomes increased 8-fold for human adenocarcinoma alveolar basal epithelial cells (A549) at pH 6.8 compared with pH 7.4
The researchers determined that EGFR-positive cells showed significantly higher localization of quantum dots (QDs) compared to EGFR-negative cells, with EGFR-positive cells treated with aptamer–QD–liposomes showing the highest transfection of QDs andmodel siRNA
Summary
Since their first published description in 1964 [1], interest in liposomes as drug carriers and delivery agents has grown exponentially, and they have become the most prominent nanoparticle (NP) drug delivery system approved for use in the clinic. Liposome–drug bioconjugates, which include release, liposome targeting moieties, Before we discuss the recent progress, it is first controlled important drug to understand some of the essential design and liposome tracking. Theseconcentration factors shouldof be drug designed based on the spatiotemporal control sustained loading becomes an important of drug delivery required for the particular application. Example, to treat a systemic infection, consideration that can affect drug release rate and For overall efficacy These factors should be it may be based useful on to have a long-circulating, slow-release liposome, whereas tumor, it may be more designed the spatiotemporal control of drug delivery required forfor thea particular application. In the sections that follow, we highlight current approaches that employ various bioconjugation strategies to optimize drug loading and release and liposome targeting. We provide a brief synopsis of the current state of preclinical liposomal systems that are in phase I or phase II trials
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
